Author

P. W. Rothlauf

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 8 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 9 Research Focus:host-pathogen & immune response· 7 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Approach:statistical model· 2

Frequent Co-Authors

S. P. J. Whelan· 8 shared Z. Liu· 8 shared M. S. Diamond· 6 shared J. B. Case· 4 shared Q. Zeng· 4 shared S. Ding· 4 shared D. H. Fremont· 3 shared H. Zhao· 3 shared

Activity by Year

2020-2021 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

8 shared papersMicrobiology

S. P. J. Whelan

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

M. Mahoney, V. C. Damalanka, M. Tartell, D. H. Chung, A. L. Lourenco, D. Pwee, A. E. Mayer Bridwell, M. Hoffmann, J. Voss, P. Karmakar, N. P. Azouz, A. M. Klinger, P. W. Rothlauf, C. E. Thompson, M. Lee, , J. W. Janetka

This paper identifies a novel class of TMPRSS2 inhibitors that effectively block SARS-CoV-2 and MERS-CoV entry and show promise as a therapeutic for COVID-19.

bioRxiv · May 6, 2021Microbiology

Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell

M. Puray-Chavez, K. M. Lapak, T. P. Schrank, J. L. Elliott, D. P. Bhatt, M. J. Agajanian, R. Jasuja, D. Q. Lawson, K. Davis, P. W. Rothlauf, H. Jo, N. Lee, K. Tenneti, J. E. Eschbach, C. Shema Mugisha, , S. B. Kutluay

This study identifies H522 cells as ACE2-negative human cells permissive to SARS-CoV-2 infection, revealing alternative receptor usage and host response mechanisms.

bioRxiv · Mar 1, 2021Microbiology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

bioRxiv · Jan 14, 2021Immunology

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

S. Ding, R. Zang, J. B. Case, M. F. Gomez Castro, Z. Liu, Q. Zeng, H. Zhao, J. Son, P. W. Rothlauf, G. Hou, S. Bose, X. Wang, M. D. Vahey, T. Kirchhausen, D. H. Fremont, , S. P. J. Whelan

The paper identifies CH25H and its product 25HC as inhibitors of SARS-CoV-2 replication by blocking membrane fusion.

Proceedings of the National Academy of Sciences · Nov 25, 2020Peer-reviewedMicrobiology

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Z. Liu, L. A. VanBlargan, L.-M. Bloyet, P. W. Rothlauf, R. E. Chen, S. Stumpf, H. Zhao, J. M. Errico, E. S. Theel, M. J. Liebeskind, B. Alford, W. J. Buchser, A. H. Ellebedy, D. H. Fremont, M. S. Diamond, S. P. J. Whelan

bioRxiv · Nov 6, 2020 · PreprintMicrobiology

JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis

J. Son, S. Huang, Q. Zeng, T. L. Bricker, J. B. Case, J. Zhou, R. Zang, Z. Liu, X. Chang, H. H. Harastani, L. Chen, M. F. Gomez Castro, Y. Zhao, H. P. Kohio, G. Hou, , S. Ding

The paper identifies JIB-04 as a broad-spectrum antiviral that inhibits SARS-CoV-2 replication and coronavirus pathogenesis in vitro and in vivo.

bioRxiv · Sep 24, 2020Microbiology

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

bioRxiv · Sep 10, 2020Microbiology

Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.

J. B. Case, P. W. Rothlauf, R. E. Chen, Z. Liu, H. Zhao, A. S. Kim, L.-M. Bloyet, Q. Zeng, S. Tahan, L. Droit, M. X. G. Ilagan, M. A. Tartell, G. K. Amarasinghe, J. P. Henderson, S. Miersch, , S. P. J. Whelan

This study develops two neutralization assays for SARS-CoV-2 using VSV and a clinical isolate, showing high concordance between monoclonal, polyclonal antibodies, and ACE2-Fc in neutralizing activity.

bioRxiv · May 18, 2020Microbiology

TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes

R. Zang, M. F. G. Castro, B. T. McCune, Q. Zeng, P. W. Rothlauf, N. M. Sonnek, Z. Liu, K. F. Brulois, X. Wang, H. B. Greenberg, M. S. Diamond, M. A. Ciorba, S. P. J. Whelan, S. Ding

This study shows SARS-CoV-2 infects human intestinal enterocytes via TMPRSS2 and TMPRSS4, but viral particles in stool are inactivated, suggesting limited fecal-oral transmission.

bioRxiv · Apr 21, 2020Microbiology

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

Y.-L. Kang, Y.-Y. Chou, P. W. Rothlauf, Z. Liu, T. K. Soh, D. Cureton, J. B. Case, R. E. Chen, M. S. Diamond, S. P. J. Whelan, T. Kirchhausen

The paper shows that PIKfyve kinase inhibitors block infection by Zaire ebolavirus and SARS-CoV-2 by preventing viral content release.

bioRxiv · Apr 21, 2020Cell Biology